Clover Biopharmaceuticals Completes Enrollment for Australian Phase II Trial of Combined Respiratory Vaccine Candidate

Stock News03-30

Clover Biopharmaceuticals (02197) has announced that patient enrollment for the Australian Phase II clinical trial of its proprietary combined respiratory vaccine candidates, SCB‑1022 (RSV+hMPV) and SCB‑1033 (RSV+hMPV+PIV3), has been completed. Developed using the company's validated protein trimer (Trimer‑Tag) vaccine technology platform, the RSV combined vaccine candidates utilize a prefusion F (Pre-F) trimer subunit vaccine protein antigen. The ongoing Phase II study for Clover's RSV vaccine candidates is a randomized, observer-blinded, multicenter clinical trial that enrolled 420 elderly subjects (aged 60–85 years) in Australia. Participants were randomly assigned to receive SCB‑1022, SCB‑1033, or a placebo. The trial is evaluating the safety, reactogenicity, and immunogenicity of the company's RSV combination vaccine candidates, with preliminary results expected in the third quarter of 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1175814653?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-30 06:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1175814653","market":"fut","top_or_hot":-1,"title":"Clover Biopharmaceuticals Completes Enrollment for Australian Phase II Trial of Combined Respiratory Vaccine Candidate","media":"Stock News","content":"<p>Clover Biopharmaceuticals (02197) has announced that patient enrollment for the Australian Phase II clinical trial of its proprietary combined respiratory vaccine candidates, SCB‑1022 (RSV+hMPV) and SCB‑1033 (RSV+hMPV+PIV3), has been completed. Developed using the company's validated protein trimer (Trimer‑Tag) vaccine technology platform, the RSV combined vaccine candidates utilize a prefusion F (Pre-F) trimer subunit vaccine protein antigen. The ongoing Phase II study for Clover's RSV vaccine candidates is a randomized, observer-blinded, multicenter clinical trial that enrolled 420 elderly subjects (aged 60–85 years) in Australia. Participants were randomly assigned to receive SCB‑1022, SCB‑1033, or a placebo. The trial is evaluating the safety, reactogenicity, and immunogenicity of the company's RSV combination vaccine candidates, with preliminary results expected in the third quarter of 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Clover Biopharmaceuticals Completes Enrollment for Australian Phase II Trial of Combined Respiratory Vaccine Candidate</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nClover Biopharmaceuticals Completes Enrollment for Australian Phase II Trial of Combined Respiratory Vaccine Candidate\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-30 06:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Clover Biopharmaceuticals (02197) has announced that patient enrollment for the Australian Phase II clinical trial of its proprietary combined respiratory vaccine candidates, SCB‑1022 (RSV+hMPV) and SCB‑1033 (RSV+hMPV+PIV3), has been completed. Developed using the company's validated protein trimer (Trimer‑Tag) vaccine technology platform, the RSV combined vaccine candidates utilize a prefusion F (Pre-F) trimer subunit vaccine protein antigen. The ongoing Phase II study for Clover's RSV vaccine candidates is a randomized, observer-blinded, multicenter clinical trial that enrolled 420 elderly subjects (aged 60–85 years) in Australia. Participants were randomly assigned to receive SCB‑1022, SCB‑1033, or a placebo. The trial is evaluating the safety, reactogenicity, and immunogenicity of the company's RSV combination vaccine candidates, with preliminary results expected in the third quarter of 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02197","symbol_name":"三叶草生物-B","start_time":0,"source_url":"","article_id":"1175814653","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1175814653","pubTimestamp":1774822943,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Clover Biopharmaceuticals (02197) has announced that patient enrollment for the Australian Phase II clinical trial of its proprietary combined respiratory vaccine candidates, SCB‑1022 (RSV+hMPV) and...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02197":"三叶草生物-B","BK1161":"生物科技"},"translate_title":"Clover Biopharmaceuticals完成呼吸道联合候选疫苗澳大利亚II期试验的招募","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02197":1},"content_text":"Clover Biopharmaceuticals (02197) has announced that patient enrollment for the Australian Phase II clinical trial of its proprietary combined respiratory vaccine candidates, SCB‑1022 (RSV+hMPV) and SCB‑1033 (RSV+hMPV+PIV3), has been completed. Developed using the company's validated protein trimer (Trimer‑Tag) vaccine technology platform, the RSV combined vaccine candidates utilize a prefusion F (Pre-F) trimer subunit vaccine protein antigen. The ongoing Phase II study for Clover's RSV vaccine candidates is a randomized, observer-blinded, multicenter clinical trial that enrolled 420 elderly subjects (aged 60–85 years) in Australia. Participants were randomly assigned to receive SCB‑1022, SCB‑1033, or a placebo. The trial is evaluating the safety, reactogenicity, and immunogenicity of the company's RSV combination vaccine candidates, with preliminary results expected in the third quarter of 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1175814653","isCrawlerRequest":true}